When Should You See a Neurologist? 8 Symptoms Not to Ignore (Western Maryland Guide)
A Western Maryland guide to 8 neurological symptoms not to ignore — headaches, numbness, memory loss, seizures, tremor, dizziness, sleep issues, and weakness.
2026 Neurology Treatment Guide: Every Major Advance, by Condition
A clear, by-condition guide to the major 2026 neurology treatment advances — migraine, Alzheimer’s, Parkinson’s, epilepsy, MS, neuropathy, sleep apnea, and stroke.
GLP-1 Drugs, Sleep, and Mood: What the Latest Research Shows
New 2026 research suggests GLP-1 drugs may lower sleep apnea severity, reduce CPAP reliance, and possibly help mood. Here’s what’s proven and what’s still early.
Can a Weight-Loss Shot Replace Your CPAP? What the FDA’s Zepbound Approval for Sleep Apnea Really Means
The FDA approved Zepbound, the first medication for obstructive sleep apnea. Here’s who it helps, whether it replaces CPAP, and how to get evaluated in Western Maryland.
Suzetrigine: A Non-Opioid Drug for Diabetic Nerve Pain Enters Phase 3
Vertex’s non-opioid drug suzetrigine entered Phase 3 trials for diabetic nerve pain. Learn what’s investigational, why it matters, and when an EMG helps.
New Non-Drug Option for Diabetic Nerve Pain: FDA Clears Axon Therapy
The FDA cleared Axon Therapy, a noninvasive magnetic nerve stimulation device for painful diabetic neuropathy. Learn how it works and who it may help.
A New Kind of MS Drug for Progressive MS: What to Know About BTK Inhibitors
BTK inhibitors are a new approach for progressive MS. Roche’s fenebrutinib hit its Phase 3 goal while Sanofi’s tolebrutinib got an FDA CRL. Here is the honest picture.
Generic Copaxone Is Here: What the First Glatiramer Acetate Generic Means for MS Costs
The FDA approved the first complex generic of Copaxone (glatiramer acetate) for relapsing MS in January 2026. Here is what it means for cost, insurance, and access.
What “Precision Medicine” Means for Epilepsy in 2026
Epilepsy care is shifting toward precision medicine and gene-targeted therapies. Learn what this means for patients and families, with examples now in trials.
2026 Neurology FDA Approvals: A Plain-English Roundup for Patients
A patient-friendly 2026 roundup of major neurology FDA approvals and decisions across Alzheimer’s, Parkinson’s, MS, epilepsy, neuropathy, and sleep apnea.